EN DE
Watch Hemo Organic Limited for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Hemo Organic Limited (HEMORGANIC) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Hemo Organic Limited stock ₹17.93, price ₹19.95, that is 10.1% below the price, quality 24 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE422G01015

HO Hemo Organic Limited logo Thin data Nov 15, 2026

Hemo Organic Limited

HEMORGANIC · BSE

Expensive (fair value 10% below the price) and weak company, but rising price: meets 1 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Expensive Growth (revenue 5y +158.4 %/yr in INR) 
Fair value ₹17.93 · Overvalued 
Quality 24/100 
Loss-making · -31.0% net margin (TTM) 
High debt 
Negative free cash flow 
Trails peers (1/8) 
Narrow moat 5/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch Hemo Organic Limited for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹77.15 ₹5.86 Fair Value ₹17.93 Oct 2017 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ₹5.86 – ₹77.15 · fair‑value band ₹13.45 – ₹22.41 · the ₹19.95 price screens above the ₹17.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Hemo Organic in your weekly email

Every Wednesday you see whether Hemo Organic is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hemo Organic Limited engages in the manufacture and sale of ayurvedik or Unani pharmaceutical preparations in India. It also engages in the manufacturing, trading, and dealing of chemicals, dyes, pigments, auxiliaries, intermediates, heavy and fine chemicals, organic and inorganic chemicals, etc.

Show moreShow less

The company was formerly known as Dinesh Allorga Limited and changed its name to Hemo Organic Limited in August 2013. The company was incorporated in 1992 and is based in Anand, India.

Stock analysis

Hemo Organic Limited (HEMORGANIC) currently trades at ₹19.95, while our estimate is ₹17.93, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹13.45 (bear) to ₹22.41 (bull), the price of ₹19.95 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Hemo Organic Limited reported revenue of ₹9.3M in FY2026 versus ₹68.3K in FY2022, a compound +241.5%/yr. Reported net income was −₹7.8M in FY2026.

Key figures

Market cap ₹137M (≈ $1.5M) Micro · P/S ratio 6.11 · EPS (TTM) ₹−2.10 · Net margin −31.0% · Return on equity −49.0% · Return on assets (EBIT) −15.4% (5-year average) · Operating margin −17.4% · Revenue (TTM) ₹23.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 95% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −10%, HEMORGANIC screens cheaper than that median.

Fair Value

Bear ₹13.45 Fair Value ₹17.93 Bull ₹22.41
Price ₹19.95 · Downside -10.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 2
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 69
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 84
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−61.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+478.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+158.4%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+49.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−591.5% (2021) → −54.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

HEMORGANIC screens overvalued: fair value 10% below the price. Compare with Merck KGaA →

Compare Hemo Organic Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −10.1% · Above median
Profitability
Return on assets −17.4% · Bottom 25%
Net margin (12 months) −31.0% · Bottom 25%
Operating margin (12 months) −17.4% · Bottom 25%
Balance sheet
Debt / equity 20.62× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (12 months) 5.81× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)20 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hemo Organic Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hemo Organic Limited Fair Value". https://www.fairvalue-calculator.com/stock/HEMORGANIC

Frequently asked questions

Is Hemo Organic Limited (HEMORGANIC) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is ₹17.93 versus a price of ₹19.95, about 10% lower (overvalued).
What is the fair value of HEMORGANIC?
Our estimate for Hemo Organic Limited is ₹17.93 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹19.95.
What is the quality score of HEMORGANIC?
Hemo Organic Limited has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hemo Organic Limited (HEMORGANIC)?
Our calculated price target is the estimate of ₹17.93 (as of Nov 15, 2026). Cautious scenario ₹13.45, optimistic scenario ₹22.41. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hemo Organic Limited stock forecast for 2026?
Our estimate puts fair value at ₹17.93, about 10% lower versus a price of ₹19.95 (overvalued). Cautious scenario ₹13.45, optimistic scenario ₹22.41. The calculation is refreshed regularly with new filings.
What is the revenue of Hemo Organic Limited (HEMORGANIC)?
Hemo Organic Limited reported trailing-twelve-month revenue of about ₹23.6M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Hemo Organic Limited (HEMORGANIC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hemo Organic Limited it is ₹17.93 per share (as of Nov 15, 2026), against a price of ₹19.95.
Is Hemo Organic Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, HEMORGANIC trades above its calculated fair value: price ₹19.95, fair value ₹17.93, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HEMORGANIC?
No. The price is what the market pays today (₹19.95); the fair value is what the company's own numbers justify (₹17.93). For Hemo Organic Limited the two are ₹2.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hemo Organic Limited worth?
The market values Hemo Organic Limited at about ₹137M (market capitalisation, as of Nov 15, 2026). Per share that is ₹19.95; our models calculate a fair value of ₹17.93 per share.
What do the bullish and bearish scenarios say about HEMORGANIC?
Our models span a range for Hemo Organic Limited: cautious scenario ₹13.45, base ₹17.93, optimistic ₹22.41 per share (as of Nov 15, 2026, price ₹19.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hemo Organic Limited (HEMORGANIC)?
Balance-sheet figures for Hemo Organic Limited (as of Nov 15, 2026): return on equity −49.0%. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is HEMORGANIC from its 52-week high?
Hemo Organic Limited trades at ₹19.95, about 18% below its 52-week high of ₹24.42 and 95% above the low of ₹10.22 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹17.93 is for.
Which stocks are comparable to Hemo Organic Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hemo Organic Limited stock attractive at the current price?
The data as of Nov 15, 2026: price ₹19.95, calculated fair value ₹17.93 (−10%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Hemo Organic Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hemo Organic Limited (HEMORGANIC)?
The closing price on Nov 16, 2026 was ₹19.95. Our estimate is ₹17.93, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hemo Organic Limited right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Hemo Organic Limited

How large is the market capitalisation of Hemo Organic Limited (HEMORGANIC)?
The market capitalisation of Hemo Organic Limited is ₹137M (≈ $1.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hemo Organic Limited (HEMORGANIC)?
The price-to-sales ratio of Hemo Organic Limited is 6.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hemo Organic Limited (HEMORGANIC)?
Earnings per share at Hemo Organic Limited are ₹−2.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hemo Organic Limited (HEMORGANIC)?
The net margin of Hemo Organic Limited is −31.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hemo Organic Limited (HEMORGANIC)?
The return on equity (ROE) of Hemo Organic Limited is −49.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hemo Organic Limited (HEMORGANIC)?
On an EBIT basis the return on assets of Hemo Organic Limited is −15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hemo Organic Limited (HEMORGANIC)?
The operating margin of Hemo Organic Limited is −17.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Hemo Organic Limited (HEMORGANIC) generate?
The free cash flow of Hemo Organic Limited is −₹14.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hemo Organic Limited (HEMORGANIC) carry?
The net debt of Hemo Organic Limited is ₹27.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hemo Organic Limited in the live analysis

One click puts Hemo Organic Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.